Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SWEATPATCH

Financiado

Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic Response

Breast Cancer (BC) is the most common cancer in Europe. In most cases, BC will present at a locally advanced or distant stage, which requiresanticancer drugs. However, there is no guarantee that the favorable drug benefit/risk bal... ver más

31/03/2028

CENTRALE LILLE INS...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

CENTRALE LILLE INSTITUT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 11 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-12

HORIZON-EIC-2023-PATHFINDEROPEN-01-01: EIC Pathfinder Open Scope:

I+D

Cerrada hace 1 año

0% 95% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

CENTRALE LILLE INSTITUT

595.18K€ | Lider

NEUROLANE LTD

N.D. | Participante

CSS -IRCCS

201.35K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BIO2011-30535-C04-01 DESARROLLO DE TECNOLOGIA ULTRASONICA DE ALTO RENDIMIENTO PAR... 121K€ Cerrado

BIO2008-06843-C04-01 AISLAMIENTO NO INVASIVO DE CELULAS TUMORALES CIRCULANTES EN... 121K€ Cerrado

VOGAS Screening of Gastric Cancer via Breath volatile organic comp... 4M€ Cerrado

PID2019-103899RB-I00 BIOSENSORES PARA DESENTRAÑAR EL LEGADO Y EL FUTURO DE LA EPI... 206K€ Cerrado

PLEC2021-007892 Plataforma (Oncodeeplasm) para inmunoensayos optoplasmónicos... 336K€ Cerrado

CTQ2012-34238 PLATAFORMAS SENSORAS BASADAS EN NUEVOS BIORRECEPTORES DE AFI... 212K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2024-03-12
Fecha Fin: 2028-03-31

Líder del proyecto

CENTRALE LILLE INSTITUT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Breast Cancer (BC) is the most common cancer in Europe. In most cases, BC will present at a locally advanced or distant stage, which requiresanticancer drugs. However, there is no guarantee that the favorable drug benefit/risk balance will align with expectations at an individual level or be maintained over time. Therefore, monitoring tumor response to treatment is critical for timely adjusting the therapeutic strategy to improve patients’ outcomes. To fulfill this unmet medical need,SWEATPATCH proposesan innovative non- invasive approach to monitor in real-time BC response to treatment, based on emerging odorous biomarkers, namely volatile organic compounds (VOCs) from sweat emanated from the breast skin. Due to their connection to breast tumor metabolism, sweat VOCs are promising candidate biomarkers for monitoring tumor response to treatment.SWEATPATCH breakthrough relies on a radically-new technology with cutting-edge straintronic microwave based on phononic metamaterials and nanomaterials chemtronics technologies to solve scientific bottlenecks for sweat VOCs analysis in the near field of cancer cells.SWEATPATCH will gather an interdisciplinary consortium of leading experts in materials, sensors, data processing, and translational/clinical oncology, from 6 countries. The consortium will develop a groundbreaking wireless Lab-on-a-Patch to (1) monitor BC therapeutic response directly from the breast surface using a novel biocompatible flexible patch combined with specific data analysis that (2) will also be adaptable to in vitro 3D culture systems of patients’ derived organoids, a tumor model avatar created from patients’ BC, which will be used for drug screening to modelize tumor response to treatment.SWEATPATCH will convey a considerable conceptual leap that will shift the current healthcare paradigm from «one-size-fit-all» monitoring to «a smart real-time personalized monitoring»synchronized to tumor biology to reach precision oncology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores